Kyverna Therapeutics (KYTX) Income from Non-Controlling Interests (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Income from Non-Controlling Interests of -$193000.0 for Q1 2026, down 493.88% on a QoQ basis from $49000.0 in Q3 2025, and down 82.08% year-over-year from -$1.1 million in Q1 2025.
Kyverna Therapeutics (KYTX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$193000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Kyverna Therapeutics | 483.78 Mn | 483.78 Mn | - | -193,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -193,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -106,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | -36,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 18,000.00 |